Literature DB >> 10505118

Allele replacement: an application that permits rapid manipulation of herpes simplex virus type 1 genomes.

B C Horsburgh1, M M Hubinette, D Qiang, M L MacDonald, F Tufaro.   

Abstract

Herpes simplex virus (HSV) is a new platform for gene therapy. We cloned the human herpesvirus HSV-1 strain F genome into a bacterial artificial chromosome (BAC) and adapted chromosomal gene replacement technology to manipulate the viral genome. This technology exploits the power of bacterial genetics and permits generation of recombinant viruses in as few as 7 days. We utilized this technology to delete the viral packaging/cleavage (pac) sites from HSV-BAC. HSV-BAC DNA is stable in bacteria and the pac-deleted HSV-BAC (p45-25) is able to package amplicon plasmid DNA as efficiently as a comparable pac-deleted HSV cosmid set when transfected into mammalian cells. Moreover, the utility of bacterial gene replacement is not limited to HSV, since most herpesviruses can be cloned as BACs. Thus, this technology will greatly facilitate genetic manipulation of all herpesviruses for their use as research tools or as vectors in gene therapy.

Entities:  

Mesh:

Year:  1999        PMID: 10505118     DOI: 10.1038/sj.gt.3300887

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  34 in total

1.  A self-recombining bacterial artificial chromosome and its application for analysis of herpesvirus pathogenesis.

Authors:  G A Smith; L W Enquist
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

2.  Construction of a self-excisable bacterial artificial chromosome containing the human cytomegalovirus genome and mutagenesis of the diploid TRL/IRL13 gene.

Authors:  Dong Yu; Gregory A Smith; Lynn W Enquist; Thomas Shenk
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

3.  The essential protein encoded by the UL31 gene of herpes simplex virus 1 depends for its stability on the presence of UL34 protein.

Authors:  G J Ye; B Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

4.  Fast screening procedures for random transposon libraries of cloned herpesvirus genomes: mutational analysis of human cytomegalovirus envelope glycoprotein genes.

Authors:  U Hobom; W Brune; M Messerle; G Hahn; U H Koszinowski
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

Review 5.  Strategies for the rapid construction of conditionally-replicating HSV-1 vectors expressing foreign genes as anticancer therapeutic agents.

Authors:  Jacqueline N Parker; Xiaojia Zheng; William Luckett; James M Markert; Kevin A Cassady
Journal:  Mol Pharm       Date:  2010-12-17       Impact factor: 4.939

6.  Human cytomegalovirus: bacterial artificial chromosome (BAC) cloning and genetic manipulation.

Authors:  Anne M Paredes; Dong Yu
Journal:  Curr Protoc Microbiol       Date:  2012-02

7.  Use of Adeno-Associated and Herpes Simplex Viral Vectors for In Vivo Neuronal Expression in Mice.

Authors:  Rachel D Penrod; Audrey M Wells; William A Carlezon; Christopher W Cowan
Journal:  Curr Protoc Neurosci       Date:  2015-10-01

8.  Transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1 for targeting prostate tumors.

Authors:  Cleo Y F Lee; Luke X X Bu; Arrigo DeBenedetti; B Jill Williams; Paul S Rennie; William W G Jia
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

9.  Replication-competent herpes simplex virus 1 isolates selected from cells transfected with a bacterial artificial chromosome DNA lacking only the UL49 gene vary with respect to the defect in the UL41 gene encoding host shutoff RNase.

Authors:  Maria Teresa Sciortino; Brunella Taddeo; Maria Giuffrè-Cuculletto; Maria Antonietta Medici; Antonio Mastino; Bernard Roizman
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

10.  The extracellular domain of herpes simplex virus gE is indispensable for efficient cell-to-cell spread: evidence for gE/gI receptors.

Authors:  Katarina Polcicova; Kim Goldsmith; Barb L Rainish; Todd W Wisner; David C Johnson
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.